A Study of Apremilast in Pediatric Participants in Children with Mild to Moderate Plaque Psoriasis

- Participants must have a weight of ≥ 20 kg. - Participant must have an age and sex specific BMI value no lower in range than the fifth percentile on the growth chart for children and adolescents. - Participant is able to swallow the study medication tablet. - Diagnosis of chronic plaque psoriasis for at least 6 months prior to screening. - Has mild to moderate plaque psoriasis at screening and Study Visit 1 as defined by: - Psoriasis Area Severity Index score 2-15, - Body surface area 2-15%, and - Static Physician Global Assessment score of 2-3 (mild to moderate) - Disease inadequately controlled by or inappropriate for topical therapy for psoriasis.

- Guttate, erythrodermic, or pustular psoriasis at screening and Study Day 1. - Psoriasis flare or rebound within 4 weeks prior to screening. - Active tuberculosis (TB) or a history of incompletely treated TB per local guidelines. - History of recurrent significant infections. - Active infection or infection treated with antibiotic treatment within 14 days of Study Day 1. - Any history of or active malignancy or myeloproliferative or lymphoproliferative disease. - Current use of the following therapies that may have a possible effect on psoriasis: - Conventional systemic therapy for psoriasis within 28 days prior to Study Day 1 (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, and fumaric acid esters). - Phototherapy treatment (ie, ultraviolet B [UVB], PUVA) within 28 days prior to Study Day 1. - Biologic therapy: o Etanercept (or biosimilar) treatment 28 days prior to Study Day 1 o Adalimumab (or biosimilar) treatment 10 weeks prior to Study Day 1 o Other TNF or IL-17 blockers (such as infliximab, certolizumab pegol, secukinumab, ixekizumab, brodalumab, or their biosimilars) within 12 weeks prior to Study Day 1 o Anti-IL-12 or anti-IL-23 treatment (such as ustekinumab, guselkumab, or tildrakizumab) within 24 weeks prior to Study Day 1. - Use of tanning booths or other ultraviolet light sources. - Answer “Yes” to any question on the Columbia-Suicide Severity Rating Scale during screening or at Study Day 1. - Female participant of childbearing potential with a positive pregnancy test assessed at screening and/or Study Day 1 by a serum and/or urine pregnancy test.